<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01398085</url>
  </required_header>
  <id_info>
    <org_study_id>UCL/10/0299</org_study_id>
    <secondary_id>2011-000144-21</secondary_id>
    <secondary_id>Cancer Research UK</secondary_id>
    <secondary_id>ISRCTN</secondary_id>
    <nct_id>NCT01398085</nct_id>
  </id_info>
  <brief_title>IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients</brief_title>
  <acronym>IoN</acronym>
  <official_title>Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      IoN is a phase II/ III trial that will look to ascertain whether or not radio-iodine ablation&#xD;
      is necessary for low risk differentiated thyroid cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase II: to determine if recruitment into a phase III trial is feasible, with a target of 10&#xD;
      patients per month during a minimum of 6 months (evaluated within months 7-18 of the trial).&#xD;
&#xD;
      Phase III: to determine whether the 5-year disease-free survival rate among patients who do&#xD;
      not have routine Radioactive iodine (RAI) ablation is non-inferior to those who do.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">March 2031</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase II: monthly patient accrual rates</measure>
    <time_frame>Evaluated within months 7-18 of the trial</time_frame>
    <description>To determine if recruitment into a phase III trial is feasible</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase III: Disease-free thyroid specific survival</measure>
    <time_frame>From randomisation until recurrence or death from thyroid cancer</time_frame>
    <description>DFS measured from randomisation until date of recurrence or death from thyroid cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase III: Mortality (cause and date of death)</measure>
    <time_frame>From randomisation until death</time_frame>
    <description>Cause and date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase III: Occurrence of loco-regional recurrence or metastatic disease</measure>
    <time_frame>After follow up is complete (estimated year 8-9 of trial)</time_frame>
    <description>Both groups will be compared to ascertain if radio-iodine results in a statistically significant reduction in risk in developing loco-regional recurrence in the low risk subgroup of patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase III: Stage of cancer at the time of recurrence, and the ability to treat this successfully</measure>
    <time_frame>After follow up is complete (estimated year 8-9 of trial)</time_frame>
    <description>Both groups will be compared to ascertain if radio-iodine results in a statistically significant difference in the stage of cancer at the time of recurrence, and the ability to treat this successfully.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase III: Health-related quality of life</measure>
    <time_frame>After follow up is complete (estimated year 8-9 of trial)</time_frame>
    <description>Quality of Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase III: Adverse events for all patients</measure>
    <time_frame>After follow up is complete (estimated year 8-9 of trial)</time_frame>
    <description>Adverse events will be collected for patients in both groups during treatment and the groups compared during analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase III: Further neck surgery</measure>
    <time_frame>After follow up is complete (estimated year 8-9 of trial)</time_frame>
    <description>The number of further neck surgeries will be collected for patients in both groups during follow up and the groups compared during analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase III: Further RAI ablations</measure>
    <time_frame>After follow up is complete (estimated year 8-9 of trial)</time_frame>
    <description>Further RAI ablation and the reasons for this</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase III: Cost-effectiveness</measure>
    <time_frame>After follow up is complete (estimated year 8-9 of trial)</time_frame>
    <description>Costs of treatment for both groups will be collected for duration of trial to see if there is a difference between the two.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">504</enrollment>
  <condition>Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>Radioactive iodine (RAI) ablation Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomised to receive Radioactive iodine (RAI) ablation I131 1.1 GBq</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Radioactive iodine (No-RAI) ablation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will be randomised to receive No Radioactive iodine (No-RAI) ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>I131 1.1 GBq</intervention_name>
    <description>Radio-iodine</description>
    <arm_group_label>Radioactive iodine (RAI) ablation Arm</arm_group_label>
    <other_name>Sodium iodide capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        TNM eligibility is assessed against TNM7 (7th edition 2009) or TNM8 (8th edition 2017, in&#xD;
        use in the UK from 01/01/2018).&#xD;
&#xD;
        Eligibility Criteria using TNM7:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Histological confirmation of well differentiated thyroid carcinoma: MDT decision for&#xD;
             inclusion based on overall clinico-pathological assessment is critical.&#xD;
&#xD;
          -  R0 total thyroidectomy (in one or two stages, no residual disease present; Rx at the&#xD;
             discretion of the MDT) within the last 6 months&#xD;
&#xD;
          -  Negative pregnancy test in women of child bearing potential&#xD;
&#xD;
          -  Aged 16 or over&#xD;
&#xD;
          -  WHO performance status 0 - 2, self-caring&#xD;
&#xD;
          -  Histological confirmation of differentiated thyroid carcinoma:MDT decision for&#xD;
             inclusion based on overall clinico-pathological assessment&#xD;
&#xD;
          -  Papillary thyroid cancer (PTC):&#xD;
&#xD;
               -  Non aggressive histological features (small foci of aggressive histology allowed&#xD;
                  at the discretion of the MDT)&#xD;
&#xD;
               -  pT1a (≤1cm) unifocal with positive level VI lymph nodes (pN1a)&#xD;
&#xD;
               -  pT1a(m): all individual foci ≤1cm&#xD;
&#xD;
               -  pT1b and pT1b(m): &gt;1-2cm&#xD;
&#xD;
               -  pT2 and pT2(m): &gt;2-4cm&#xD;
&#xD;
               -  pT3 and pT3(m): &gt;4cm confined to the thyroid&#xD;
&#xD;
               -  pT3 R0 +/- (m): any size with minimal ETE if recommended by the MDT&#xD;
&#xD;
               -  pN0&#xD;
&#xD;
               -  pN1a&#xD;
&#xD;
               -  pNX&#xD;
&#xD;
          -  Follicular thyroid cancer (FTC) (including oncocytic or Hürthle cell cancer):&#xD;
&#xD;
             o minimally invasive FTC -which are considered low risk and are recommended by the&#xD;
             specialist MDT based on overall clinico-pathological assessment&#xD;
&#xD;
               -  pT1b and pT2: &gt;1-4cm intrathyroidal&#xD;
&#xD;
               -  pT3 R0:any size up to 4 cm with minimal ETE if recommended by the MDT&#xD;
&#xD;
          -  Histological material available for Central Review (see section 9.7)&#xD;
&#xD;
          -  Willing to use contraception for the duration of the trial until 6 months post&#xD;
             radioiodine treatment (for females) or 4 months post treatment (for males) (see&#xD;
             section 6.4.2), if allocated to the ablation group.&#xD;
&#xD;
        NB: Multifocal tumours (≥2 foci) of all histological types should be designated with &quot;(m)&quot;,&#xD;
        and the size of the largest focus determines the classification (as described in the TNM&#xD;
        7th edition). For example, if there are two foci, one 0.8cm and the other 3cm, the&#xD;
        classification is based on the 3cm focus; i.e. pT2(m).&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  pT1a - Papillary and Follicular carcinoma which is unifocal and ≤1cm in size, without&#xD;
             any positive nodes or unfavourable clinical features, treated by lobectomy.&#xD;
&#xD;
          -  Up to 4cm non-invasive Encapsulated Follicular Variant of Papillary Thyroid Cancer&#xD;
             (eFVPTC) with no capsular or vascular invasion (&gt;4 cm can be included at the&#xD;
             discretion of the MDT)&#xD;
&#xD;
          -  non-invasive follicular tumour with papillary-like nuclei (NIFTP)&#xD;
&#xD;
          -  Anaplastic, poorly differentiated or medullary carcinoma&#xD;
&#xD;
          -  R1 or R2 thyroidectomy&#xD;
&#xD;
          -  Patients with:&#xD;
&#xD;
               -  pN1b&#xD;
&#xD;
               -  M1&#xD;
&#xD;
          -  Aggressive Papillary thyroid cancer with any of the following features:&#xD;
&#xD;
               -  Widely invasive&#xD;
&#xD;
               -  Poorly differentiated&#xD;
&#xD;
               -  Anaplastic&#xD;
&#xD;
               -  Tall cell&#xD;
&#xD;
               -  Columnar cell&#xD;
&#xD;
               -  Diffuse sclerosing variants&#xD;
&#xD;
          -  Follicular thyroid cancer/Hürthle cell cancer with any of the following features:&#xD;
&#xD;
               -  Tumours greater than 4cm&#xD;
&#xD;
               -  Widely invasive&#xD;
&#xD;
               -  Poorly differentiated&#xD;
&#xD;
               -  Anaplastic&#xD;
&#xD;
          -  Incomplete resection or lobectomy&#xD;
&#xD;
          -  pT4a and pT4b or macroscopic and microscopic tumour invasion of loco-regional tissues&#xD;
             or structures&#xD;
&#xD;
          -  Pregnant women or women who are breast feeding&#xD;
&#xD;
          -  Patients who have had CT performed with iv contrast less than 2-3 months before&#xD;
             ablation&#xD;
&#xD;
          -  Previous treatment for thyroid cancer (except surgery in last 6 months)&#xD;
&#xD;
          -  Previous malignancies with limited life expectancy or likely to interfere with the&#xD;
             patient's ability to be able to comply with treatment and/or follow-up for at least 5&#xD;
             years&#xD;
&#xD;
          -  The following GI conditions: dysphagia, oesophageal stricture, active gastritis,&#xD;
             gastric erosions, peptic ulcer, suspected reduced gastrointestinal motility&#xD;
&#xD;
          -  MDT decision against ablation or suitability for trial in light of severe co-morbid&#xD;
             condition/s including:&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Recent myocardial infarction or cerebrovascular accident (CVA)&#xD;
&#xD;
               -  Severe labile hypertension&#xD;
&#xD;
               -  Any patient who cannot comply with radiation protection including:&#xD;
&#xD;
                    -  patients with learning difficulties&#xD;
&#xD;
                    -  patients with dementia&#xD;
&#xD;
                    -  patients with a tracheostomy that require nursing care&#xD;
&#xD;
                    -  patients requiring frequent nursing/ medical supervision&#xD;
&#xD;
        Eligibility Criteria using TNM8:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Histological confirmation of well differentiated thyroid carcinoma: MDT decision for&#xD;
             inclusion based on overall clinico-pathological assessment is critical.&#xD;
&#xD;
          -  R0 total thyroidectomy (in one or two stages, no residual disease present; Rx at the&#xD;
             discretion of the MDT) within the last 6 months&#xD;
&#xD;
          -  Negative pregnancy test in women of child bearing potential&#xD;
&#xD;
          -  Aged 16 or over&#xD;
&#xD;
          -  WHO performance status 0 - 2, self-caring&#xD;
&#xD;
          -  Histological confirmation of differentiated thyroid carcinoma:MDT decision for&#xD;
             inclusion based on overall clinico-pathological assessment&#xD;
&#xD;
          -  Papillary thyroid cancer (PTC):&#xD;
&#xD;
               -  Non aggressive histological features (small foci of aggressive histology allowed&#xD;
                  at the discretion of the MDT)&#xD;
&#xD;
               -  pT1a (≤1cm) unifocal with positive level VI lymph nodes (pN1a)&#xD;
&#xD;
               -  pT1a(m): all individual foci ≤1cm&#xD;
&#xD;
               -  pT1b and pT1b(m): &gt;1-2cm&#xD;
&#xD;
               -  pT2 and pT2(m): &gt;2-4cm&#xD;
&#xD;
               -  pT3a and pT3a(m): &gt;4cm confined to thyroid&#xD;
&#xD;
               -  pT1a/1b/2/3 (where minimal microscopic extra thyroidal extension (ETE) does not&#xD;
                  change the T score) +/- (m): any size with minimal ETE if recommended by the MDT&#xD;
&#xD;
               -  pN0&#xD;
&#xD;
               -  pN1a&#xD;
&#xD;
               -  pNX&#xD;
&#xD;
          -  Follicular thyroid cancer (FTC) (including oncocytic or Hürthle cell cancer):&#xD;
&#xD;
             o minimally invasive FTC -which are considered low risk and are recommended by the&#xD;
             specialist MDT based on overall clinico-pathological assessment&#xD;
&#xD;
               -  pT1b and pT2: &gt;1-4cm intrathyroidal&#xD;
&#xD;
               -  pT1a/1b/2/3a (where minimal microscopic ETE does not change the T score): any&#xD;
                  size up to 4 cm with minimal ETE if recommended by the MDT&#xD;
&#xD;
          -  Histological material available for Central Review (see section 9.7)&#xD;
&#xD;
          -  Willing to use contraception for the duration of the trial until 6 months post&#xD;
             radioiodine treatment (for females) or 4 months post treatment (for males) (see&#xD;
             section 6.4.2), if allocated to the ablation group.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  pT1a - Papillary and Follicular carcinoma which is unifocal and ≤1cm in size, without&#xD;
             any positive nodes or unfavourable clinical features, treated by lobectomy.&#xD;
&#xD;
          -  Up to 4cm non-invasive Encapsulated Follicular Variant of Papillary Thyroid Cancer&#xD;
             (eFVPTC) with no capsular or vascular invasion (&gt;4 cm can be included at the&#xD;
             discretion of the MDT)&#xD;
&#xD;
          -  non-invasive follicular tumour with papillary-like nuclei (NIFTP)&#xD;
&#xD;
          -  Anaplastic, poorly differentiated or medullary carcinoma&#xD;
&#xD;
          -  R1 or R2 thyroidectomy&#xD;
&#xD;
          -  Patients with:&#xD;
&#xD;
               -  pN1a with level VII involvement&#xD;
&#xD;
               -  pN1b&#xD;
&#xD;
               -  M1&#xD;
&#xD;
          -  Aggressive Papillary thyroid cancer with any of the following features:&#xD;
&#xD;
               -  Widely invasive&#xD;
&#xD;
               -  Poorly differentiated&#xD;
&#xD;
               -  Anaplastic&#xD;
&#xD;
               -  Tall cell&#xD;
&#xD;
               -  Columnar cell&#xD;
&#xD;
               -  Diffuse sclerosing variants&#xD;
&#xD;
          -  Follicular thyroid cancer/Hürthle cell cancer with any of the following features:&#xD;
&#xD;
               -  Tumours greater than 4cm&#xD;
&#xD;
               -  Widely invasive&#xD;
&#xD;
               -  Poorly differentiated&#xD;
&#xD;
               -  Anaplastic&#xD;
&#xD;
          -  Incomplete resection or lobectomy&#xD;
&#xD;
          -  pT3b, pT4a and pT4b or macroscopic and microscopic tumour invasion of loco-regional&#xD;
             tissues or structures&#xD;
&#xD;
          -  Pregnant women or women who are breast feeding&#xD;
&#xD;
          -  Patients who have had CT performed with iv contrast less than 2-3 months before&#xD;
             ablation&#xD;
&#xD;
          -  Previous treatment for thyroid cancer (except surgery in last 6 months)&#xD;
&#xD;
          -  Previous malignancies with limited life expectancy or likely to interfere with the&#xD;
             patient's ability to be able to comply with treatment and/or follow-up for at least 5&#xD;
             years&#xD;
&#xD;
          -  The following GI conditions: dysphagia, oesophageal stricture, active gastritis,&#xD;
             gastric erosions, peptic ulcer, suspected reduced gastrointestinal motility&#xD;
&#xD;
          -  MDT decision against ablation or suitability for trial in light of severe co-morbid&#xD;
             condition/s including:&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Recent myocardial infarction or cerebrovascular accident (CVA)&#xD;
&#xD;
               -  Severe labile hypertension&#xD;
&#xD;
               -  Any patient who cannot comply with radiation protection including:&#xD;
&#xD;
                    -  patients with learning difficulties&#xD;
&#xD;
                    -  patients with dementia&#xD;
&#xD;
                    -  patients with a tracheostomy that require nursing care&#xD;
&#xD;
                    -  patients requiring frequent nursing/ medical supervision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ujjal Mallick, MBBS, Master of Surgery, FRCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Newcastle-upon-Tyne Hospitals NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Ledermann</last_name>
    <role>Study Director</role>
    <affiliation>University College London (Joint UCLH &amp; UCL Biomedical Research Unit)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brighton and Sussex University Hospitals NHS Trust</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Bristol NHS Foundation Trust</name>
      <address>
        <city>Bristol</city>
        <zip>BS1 3NU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Kent Hospitals University NHS Foundation Trust</name>
      <address>
        <city>Canterbury</city>
        <zip>CT1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Essex Hospitals Services NHS Trust</name>
      <address>
        <city>Chelmsford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Hospitals NHS Trust</name>
      <address>
        <city>Cheltenham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Derby hospital NHS foundation trust</name>
      <address>
        <city>Derby</city>
        <zip>DE223NE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Lothian</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter NHS Trust</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glasgow and Clyde NHS Trust</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Surrey County Hospital NHS Foundation Trust</name>
      <address>
        <city>Guildford</city>
        <zip>GU1 4JW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ipswich Hospital NHS Trust</name>
      <address>
        <city>Ipswich</city>
        <zip>IP4 5PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Leicester NHS Trust</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guys and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maidstone and Tunbridge Wells NHS Trust</name>
      <address>
        <city>Maidstone</city>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Tees Hospitals NHS Trust</name>
      <address>
        <city>Middlesbrough</city>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velindre NHS Trust</name>
      <address>
        <city>Nantgarw</city>
        <zip>CF15 7QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle upon Tyne Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospitals NHS Trust</name>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portsmouth Hospitals NHS Trust</name>
      <address>
        <city>Portsmouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southend University Hospitals NHS Trust</name>
      <address>
        <city>Southend</city>
        <zip>SS0 0RY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East and North Herts</name>
      <address>
        <city>Stevenage</city>
        <zip>SG1 4AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Wolverhampton NHS Trust</name>
      <address>
        <city>Wolverhampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.ctc.ucl.ac.uk/</url>
    <description>Cancer Research UK &amp; UCL Cancer Trials Centre website</description>
  </link>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 6, 2011</study_first_submitted>
  <study_first_submitted_qc>July 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2011</study_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Papillary thyroid carcinoma</keyword>
  <keyword>Follicular thyroid carcinoma</keyword>
  <keyword>Hurthle cell carcinoma of the thyroid</keyword>
  <keyword>Iodine Radioisotopes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

